Key result
Confirmed COVID-19 is linked to higher cardiovascular prescription adherence at 30 to 60 days post-discharge.
Why the study?
Does the quality of cardiovascular pharmacotherapy change during the first year after hospitalization for COVID-19?
Cohort (n=504)
Does the quality of cardiovascular pharmacotherapy change during the first year after hospitalization for COVID-19?
p-value: p=0.009
The quality of cardiovascular pharmacotherapy significantly declines during the first year after hospitalization for COVID-19, highlighting the need for improved outpatient follow-up.
Aim. To evaluate the medical treatment of patients with cardiovascular disease (CVD) during the first year of follow-up after hospitalization for coronavirus disease 2019 (COVID-19) in a prospective registry. Material and methods. The material for the study was obtained from the database of the TARGET-VIP inhospital registry. The registry included 1130 people. Of 863 patients discharged from the hospital with a diagnosis of COVID-19, 473 (548%) patients with CVD were selected, and 31 (40,8%) patients were selected from 76 patients in whom the diagnosis of COVID-19 was not confirmed with CVD. Results. At the stage of discharge from the hospital, the quality of therapy for CVD was insufficient on average, the frequency of proper prescriptions was 59,5%. During the first year, there was a significant trend towards a decrease in the prevalence of antihypertensive therapy for hypertension (p=0,018), anticoagulants for atrial fibrillation (p<0,001) and an increase in prescribing angiotensinconverting enzyme inhibitors/angiotensin receptor blockers for heart failure (p=0,037). The average prevalence of prescribing proper cardiovascular pharmacotherapy after 30-60 days and 6 months of follow-up was significantly less than at discharge from the hospital. In both groups of patients, when comparing the average frequency of compliance with proper prescriptions at all follow-up periods, as well as when comparing these indicators between groups, no significant differences were found, with the exception of the stage of 30-60 days after discharge from the hospital (p=0,009). Conclusion. In the TARGET-VIP registry after discharge from the hospital, the prevalence of proper appointments for CVD was insufficient. During the first year of observation, patients with CVD showed a significant decrease in the frequency of proper prescription of antihypertensive therapy for hypertension and anticoagulants for atrial fibrillation. When comparing groups of patients with confirmed and non-confirmed COVID-19, a higher average rate of adherence to proper prescriptions was found in patients with confirmed COVID-19. However, significant differences were found only 30-60 days after discharge.
No takes yet. Share an insight, caveat, or question.
Kutishenko et al. (2023) conducted a cohort in Cardiovascular disease and COVID-19 (n=504). Confirmed COVID-19 vs. Unconfirmed COVID-19 was evaluated on Adherence to proper cardiovascular prescriptions (p=0.009). Patients with confirmed COVID-19 had a higher average rate of adherence to proper cardiovascular prescriptions compared to those with unconfirmed COVID-19 at 30-60 days post-discharge (p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: